Company debuts catalog of validated,
recombinant, specific antibodies against difficult protein targets,
providing only the highest quality reagents for life sciences
research
PHILADELPHIA, May 9, 2024
/PRNewswire/ -- Emerging from stealth mode today, Cell Surface Bio
(CSB) launches VeRSaMAb research antibodies with the vision of
delivering "antibodies that always work," answering the call of the
scientific community for reliable reagents with uncompromising
quality. Providing monoclonal antibodies that are extensively
validated, recombinantly cloned, and exquisitely specific, CSB is
being built to transform the >$10
billion antibody reagent market where currently half of the
antibodies sold do not work as designed.
View Cell Surface Bio's mission and the
VeRSaMAb catalog
Validated Antibodies with Unparalleled Specificity
VeRSaMAbs are produced at CSB and extensively characterized to
ensure reliable results in customers' experiments every time. Now
available for purchase, VeRSaMAbs are:
- Validated for flow cytometry, immunofluorescence, and
other applications
- Recombinantly cloned for batch-to-batch consistency,
enhanced detection, and reproducible results
- Specific for only the target of interest as assessed
across 6,000 native proteins of the Membrane Proteome Array™
Transforming Life Science Reagents
"Cell Surface Bio was created by scientists for scientists,"
explained Benjamin Doranz, PhD,
Co-founder of Cell Surface Bio. "Every researcher I've met,
myself included, knows the frustration of time wasted in the lab
running experiments with antibodies that simply do not work. Our
goal is to provide researchers with only the highest quality
monoclonal antibodies that are fully validated and engineered for
the highest sensitivity of detection, so that they always
work in our customers' experiments."
A spin-out of Philadelphia's
Integral Molecular, CSB leverages the parent company's 20+ years of
expertise developing and characterizing therapeutic antibodies that
target complex and conserved proteins on the cell surface. CSB's
VeRSaMAbs are derived using the same next-generation platform used
to isolate best-in-class drugs, featuring high-throughput mRNA
immunization, Lipoparticles™ (virus-like particles) for
high-concentration presentation of structurally intact membrane
proteins, divergent species (chickens) to generate antibodies
against conserved epitopes, and optimized protocols for the
isolation of rare antibodies, even for membrane proteins embedded
in a lipid bilayer.
VeRSaMAbs are available for a wide range of protein targets
across scientific fields, including immunology, oncology, and
virology, and CSB's catalog will continue to expand as MAbs are
validated. Visit CSB to suggest new antibodies to add to the
catalog!
About Cell Surface Bio
Cell Surface Bio's mission is
to provide researchers with only the highest quality antibodies,
because as fellow scientists, we know that your time in the lab is
valuable. CSB's VeRSaMAb antibodies are built on 20+ of expertise
in discovering and characterizing antibodies against the most
difficult cell surface proteins. VeRSaMAbs are Validated,
Recombinant, and Specific to ensure reliable results every
time.
Follow CSB on LinkedIn.
Press Contact:
Soma Banik, PhD, Director of Public
Relations
Cell Surface Bio
info@cellsurfacebio.com
cellsurfacebio.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/antibody-startup-emerges-from-stealth-cell-surface-bio-set-to-transform-the-10b-antibody-reagent-market-302140224.html
SOURCE Cell Surface Bio